ES2188581T3 - Modulacion por oligonucleotidos de la adherencia celular. - Google Patents

Modulacion por oligonucleotidos de la adherencia celular.

Info

Publication number
ES2188581T3
ES2188581T3 ES91914455T ES91914455T ES2188581T3 ES 2188581 T3 ES2188581 T3 ES 2188581T3 ES 91914455 T ES91914455 T ES 91914455T ES 91914455 T ES91914455 T ES 91914455T ES 2188581 T3 ES2188581 T3 ES 2188581T3
Authority
ES
Spain
Prior art keywords
modulation
oligonucleotides
respond
diseases
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91914455T
Other languages
English (en)
Inventor
Clarence Frank Bennett
Christopher K Mirabelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2188581T3 publication Critical patent/ES2188581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Storage Device Security (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTAN COMPOSICIONES Y METODOS PARA EL TRATAMIENTO Y LA DIAGNOSIS DE ENFERMEDADES QUE RESPONDEN AL TRATAMIENTO DE MODULACION DE LA SINTESIS DEL METABOLISMO DE LAS MOLECULAS DE ADHESION INTERCELULAR. DE ACUERDO CON CONFORMACIONES MAS ADECUADAS, SE SUMINISTRAN OLIGONUCLEOTIDOS Y ANALOGOS DE OLIGONUCLEOTIDOS QUE SON ESPECIFICAMENTE HIBRIDIZABLES CON ACIDOS NUCLEICOS QUE CODIFICAN LA MOLECULA 1 DE ADHESION INTERCELULAR, LA MOLECULA 1 DE ADHESION DE LAS CELULAS VASCULARES, Y DE LA MOLECULA 1 DE ADHESION DE LOS LEUCOCITOS ENDOTELIALES. EL OLIGONUCLEOTIDO COMPRENDE UNIDADES NUCLEOTIDAS SUFICIENTES EN IDENTIDAD Y NUMERO PARA EFECTUAR DICHA HIBRIDACION ESPECIFICA. EN OTRAS CONFORMACIONES, LOS OLIGONUCLEOTIDOS SON ESPECIFICAMENTE HIBRIDIZABLES CON UNA ZONA DE INICIACION DE TRANSCRIPCION, UNA ZONA DE INICIACION DE TRANSFORMACION, LAS SECUENCIAS 5'' NO TRANSFORMADAS, LAS SECUENCIAS 3'' NO TRANSFORMADAS, Y CONSECUENCIAS DE INTERVENCION. SE PRESENTAN METODOS PARA TRATAR ANIMALES QUE SUFREN DE ENFERMEDADES QUE RESPONDEN A LA INTERVENCION TERAPEUTICA MEDIANTE LA MODULACION DE LAS PROTEINAS DE ADHESION CELULAR CON UN OLIGONUCLEOTIDO O UN ANALOGO DE OLIGONUCLEOTIDO ESPECIFICAMENTE HIBRIDIZABLE CON EL RNA O EL DNA QUE SE CORRESPONDE CON UNA DE LAS PROTEINAS MENCIONADAS ANTERIORMENTE. TAMBIEN SE HAN DESCUBIERTO METODOS PARA EL TRATAMIENTO DE ENFERMEDADES QUE RESPONDEN A LA MODULACION DE LAS MOLECULAS DE ADHESION CELULAR.
ES91914455T 1990-08-14 1991-07-23 Modulacion por oligonucleotidos de la adherencia celular. Expired - Lifetime ES2188581T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56728690A 1990-08-14 1990-08-14

Publications (1)

Publication Number Publication Date
ES2188581T3 true ES2188581T3 (es) 2003-07-01

Family

ID=24266532

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91914455T Expired - Lifetime ES2188581T3 (es) 1990-08-14 1991-07-23 Modulacion por oligonucleotidos de la adherencia celular.

Country Status (14)

Country Link
EP (1) EP0544716B1 (es)
JP (1) JP2732544B2 (es)
KR (1) KR960009261B1 (es)
AT (1) ATE230023T1 (es)
AU (1) AU641539B2 (es)
BR (2) BR9106746A (es)
CA (1) CA2089563C (es)
DE (1) DE69133180T2 (es)
DK (1) DK0544716T3 (es)
ES (1) ES2188581T3 (es)
FI (1) FI930627A0 (es)
HU (1) HU217107B (es)
NO (1) NO930513L (es)
WO (1) WO1992003139A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) * 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
BR9307844A (pt) * 1992-01-31 1996-01-09 Univ California Processo para a formaçao de uma célula livre de antigenes para transplante célula livre de antigenes para transplante oligonucleotideo capaz de ligaçao a uma sequéncia nucleotidea antigene para transplante oligonucleotideo para utilizaçao na preparaçao de uma composiçao para o tratamento de células alvo orgao doador universal e processo para o tratamento de um individuo com uma doença autoimune
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
JP2732546B2 (ja) * 1992-09-02 1998-03-30 アイシス・ファーマシューティカルス・インコーポレーテッド 細胞接着のオリゴヌクレオチド調節
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
JPH08113591A (ja) * 1994-10-14 1996-05-07 Taiho Yakuhin Kogyo Kk オリゴヌクレオチド及びこれを有効成分とする制癌剤
EP0831854A4 (en) * 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
CN104531843A (zh) * 2014-12-04 2015-04-22 杭州中翰金诺生物信息技术有限公司 肝癌诊断标志物黑素瘤细胞黏附分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3056889A (en) * 1988-01-21 1989-08-11 Yale University Selective inhibition of gene expression by photoactivatable oligonucleotides
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
KR930701180A (ko) 1993-06-11
JP2732544B2 (ja) 1998-03-30
NO930513L (no) 1993-04-01
EP0544716A1 (en) 1993-06-09
NO930513D0 (no) 1993-02-12
EP0544716A4 (en) 1994-09-14
KR960009261B1 (en) 1996-07-16
HU217107B (hu) 1999-11-29
DE69133180T2 (de) 2003-07-24
HUT68322A (en) 1995-06-28
BR9106746A (pt) 1993-07-20
ATE230023T1 (de) 2003-01-15
BR1100617A (pt) 2000-06-13
CA2089563C (en) 2004-04-06
FI930627A7 (fi) 1993-02-12
FI930627A0 (fi) 1993-02-12
EP0544716B1 (en) 2002-12-18
AU8313091A (en) 1992-03-17
HU9300373D0 (en) 1993-05-28
DE69133180D1 (de) 2003-01-30
DK0544716T3 (da) 2003-03-17
CA2089563A1 (en) 1992-02-15
AU641539B2 (en) 1993-09-23
JPH05508998A (ja) 1993-12-16
WO1992003139A1 (en) 1992-03-05

Similar Documents

Publication Publication Date Title
FI950948A0 (fi) Soluadheesion oligonukleotidimodulaatio
ES2188581T3 (es) Modulacion por oligonucleotidos de la adherencia celular.
AR015926A1 (es) Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades
ES2170065T3 (es) Modulacion de la proteina quinasa c por oligonucleotidos.
NO973685L (no) Multi-tumor avvikende vekstgener
EP0830139A4 (en) MODIFIED MYELIN PROTEIN MOLECULES
ES2157330T3 (es) Composicion que comprende aril-alquil-amina meta substituida, usos terapeuticos y diagnosticos.
EE200200049A (et) Polümorfismid inimese MDR-1 geenis ning nende kasutamine diagnostikas ja terapeutilistes rakendustes
KR930702995A (ko) 세포증식 매트릭스 및 그 용도
ES2267566T3 (es) Procedimiento de identificacion de nuevos genes implicados en la regulacion de la angiogenesis, estudio de estos genes y su utilizacion con fines terapeuticos.
SATHANANTHAN et al. Behavioural and biochemical effects of L-Dopa in psychiatric patients
ROE The affinity of hydroxystilbamidine for psoriatic lesions
Siddiqui et al. Embryonic gene regulation: role of an inducer RNA in manipulation of embryonic gene functions
Lasfargues Introduction of Madame Emilienne Wolff and Professor Etienne Wolff
OVA et al. Post-burn changes in basic biochemical indices in rat liver tissue
Chowdhury The role of peptides and other transmitters in the regulation of dopamine synthesis in the rat brain.
FREEDMAN chemistry and neuropharmacology are lacking and some of thespecialized articles would not today be considered the latest contribution in the field. Both neophyte and specialist will, nevertheless, find an orientation here which many medical and graduate schools must rapidly incorporate into their teaching programs.
Myers ISOLATION AND CHARACTERIZATION OF EARLY-REPLICATING AND LATE-REPLICATING DNA OF THE CHINESE HAMSTER
White Human embryo research.